PNT - POINT Biopharma Global GAAP EPS of $1.53 revenue of $226.58M March, 27 2023 09:41 AM POINT Biopharma Global Inc. 2023-03-27 09:41:17 ET POINT Biopharma Global press release ( NASDAQ: PNT ): Q4 GAAP EPS of $1.53. Revenue of $226.58M. Cash, cash equivalents and investments were $541.3 million as of December 31, 2022, For further details see: POINT Biopharma Global GAAP EPS of $1.53, revenue of $226.58M